Numerous animal models have shown that combining radiotherapy with IL-2 has a synergistic antitumor effect (20–23) and has been shown to be useful clinically in oral cancer (24), renal cell carcinoma (25), and prostate cancer (26). The gene discussed is IL2; the disease is lip and oral cavity carcinoma.